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In The Lancet Diabetes & Endocrinology, Helen Booth 
and colleagues1 report the results of a population-
based matched cohort study that assessed the eﬀ ect 
of bariatric surgery on development of type 2 diabetes. 
2167 obese adults without diabetes who underwent 
bariatric surgery were compared with 2167 controls 
matched for age, sex, BMI, and HbA1c who did not have 
bariatric surgery. With a median follow-up of 2·8 years 
(maximum 7 years), bariatric surgery reduced the risk 
of developing diabetes by 80% (adjusted hazard ratio 
0·20, 95% CI 0·13–0·30; p<0·0001).1 These ﬁ ndings are 
important because they provide further evidence that 
bariatric surgery can reduce the risk of type 2 diabetes in 
obese people. 
Booth and colleagues’ data1 conﬁ rm the ﬁ ndings of 
the Swedish Obese Subjects (SOS) study,2 in which a 
cohort of obese individuals was followed up for 15 years. 
Importantly, the present study provides information 
about contemporary procedures such as laparoscopic 
adjustable banding, sleeve gastrectomy, and gastric 
bypass, whereas the SOS study used the now obsolete 
technique of vertical banded gastroplasty in most 
patients. However, Booth and colleagues obtained data 
retrospectively from a UK database (Clinical Practice 
Research Datalink [CPRD]), whereas data for the SOS 
study were gathered prospectively. Furthermore, 
matched controls in the present study probably did not 
undergo obesity treatment, unlike controls in the SOS 
study, who were assigned to an intensive weight-loss 
programme.
Unfortunately, despite best matching eﬀ orts, the 
patients and controls analysed by Booth and colleagues1 
diﬀ ered widely in terms of medical monitoring. Not 
only did controls—distilled from CPRD data—not 
undergo substantial obesity treatment but also they 
seemingly did not beneﬁ t from standard medical care. 
Despite these adults being obese, 27% of controls 
had missing values for blood pressure and 68% had 
missing cholesterol data, compared with 1% and 26%, 
respectively, of bariatric surgery patients. The frequency 
of missing data in the control group seems to conﬁ rm 
widely held beliefs that many family doctors do not 
view obesity as a disease and think obese people do 
not need treatment and monitoring. Conversely, the 
bariatric surgery patients, who were treated by the most 
active means against obesity (ie, surgery), are clearly 
a select category of individuals who were monitored 
closely, rather than being broadly representative of the 
UK population, as claimed by Booth and colleagues.1 
Indicative for the selection process is that close to 30% of 
bariatric surgery patients were excluded from the study 
because of pre-existing type 2 diabetes, an unusually 
high number compared with published data.3 Moreover, 
a higher proportion of surgical patients than controls 
were taking antihypertensives and lipid-lowering drugs, 
which suggests that the bariatric surgery patients were 
probably being monitored more carefully than controls, 
constituting a substantial risk for bias.
Booth and colleagues did not address the mechanism 
by which bariatric surgery aﬀ ects glucose metabolism 
and, hence, the incidence of de-novo type 2 diabetes. 
A well-recognised mechanism of diabetes remission is 
weight loss, with more weight loss leading to a higher 
chance of remission.4 Similarly, in people without 
diabetes, more weight loss probably reduces the risk 
of developing type 2 diabetes. This mechanism could 
account for why the present results show that the risk of 
developing diabetes in the subgroup of bariatric surgery 
patients that were the least obese (BMI <35 kg/m²), 
and hence with less weight to lose, was only slightly 
smaller than that of matched controls. However, the 
incompleteness of weight data prevents adequate 
assessment of a possible link between a smaller amount 
of weight loss, or weight regain, and development of 
type 2 diabetes. Furthermore, Booth and colleagues 
did not address whether factors beyond weight loss 
(eg, anatomical changes induced by some bariatric 
surgical procedures) aﬀ ected the development of 
de-novo type 2 diabetes. Follow-up was short—most 
patients were followed up for less than 4 years—which 
is key because most patients who undergo bariatric 
procedures regain weight over time, an important 
consideration in the context of diabetes.5 In a study 
of patients with type 2 diabetes at baseline who were 
followed up over 8 years,6 more than 40% of patients 
who underwent gastric bypass relapsed after initial 
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remission from diabetes. In that study, no absolute 
link was noted between relapse of diabetes and weight 
regain;6 thus, other factors seem to aﬀ ect the natural 
history of type 2 diabetes after bariatric surgery. 
Hence, whether altered anatomy after bariatric surgery 
provides continued protection against de-novo type 2 
diabetes in the case of weight regain remains an open 
question.
Although the results of Booth and colleagues bring us 
a step closer to conﬁ rming the eﬀ ect of bariatric surgery 
on the incidence of de-novo type 2 diabetes, many 
questions still remain unanswered, and more evidence 
is needed to convince endocrinologists about the nature 
of this eﬀ ect.
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Gestational diabetes in China: challenges and coping strategies
Gestational diabetes is a common medical complication 
in pregnancy and is rapidly increasing worldwide. 
China has an estimated 16 million births per year, and 
the increasing prevalence of gestational diabetes has 
become a huge burden. Gestational diabetes brings 
health issues for both mothers and oﬀ spring, not 
only early complications, but also long-term eﬀ ects.1 
Additionally, women with gestational diabetes have 
a higher chance of developing type 2 diabetes,2 the 
burden of which is also increasing in China. Diagnosing 
and treating gestational diabetes with scarce health 
resources, particularly in rural areas, are ongoing 
challenges for the management of the disease in China.
There are no uniform diagnostic criteria for 
gestational diabetes in China. Most hospitals diagnose 
gestational diabetes based on US National Diabetes 
Data Group (NDDG) criteria, but with a 75 g oral glucose 
tolerance test (OGTT) instead of a 100 g OGTT. In 2010, 
the International Association of Diabetes and Pregnancy 
Study Groups (IADPSG)3 recommended the following 
diagnostic criteria when at least one cut-point was 
reached based on a 2-h 75 g OGTT: a fasting plasma 
glucose (FPG) of 5·1 mmol/L (92 mg/dL) or more, a 1-h 
plasma glucose of 10·0 mmol/L (180 mg/dL) or more, 
or a 2-h plasma glucose of 8·5 mmol/L (153 mg/dL) 
or more. Because there were no data from mainland 
China, the IADPSG criteria needed to be validated 
before guidelines for gestational diabetes diagnosis 
were changed. 75 g OGTT data obtained from a cohort 
of 14 593 pregnant women in Peking University 
First Hospital were reanalysed using the IADPSG 
recommended criteria.4 According to NDDG cut-oﬀ 
values 8·9% of pregnant women had abnormal glucose 
results (4·5% having gestational diabetes and 4·4% 
having gestational impaired glucose tolerance), whereas 
applying IADPSG criteria identiﬁ ed 14·7% of women as 
being aﬀ ected by gestational diabetes. The additional 
patients captured by the IADPSG criteria, with mild 
hyperglycaemia, had a higher incidence of macrosomia, 
large for gestational age infants, and were more likely 
to deliver by caesarean section compared with women 
without gestational diabetes.4
After reviewing these data, the Ministry of Health of 
China accepted the IADPSG criteria and published the 
uniform diagnostic criteria for gestational diabetes 
on July 1, 2011. The criteria quickly gained acceptance 
throughout China. In a 2013 cohort study5 of 
17 186 pregnant women from 13 hospitals throughout 
China that applied these criteria, the incidence of 
gestational diabetes was 17·5%.
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